Claim Check: What the Galleri Blood Test Can and Can't Tell You

This page looks at Galleri, a blood test sold as a way to find many cancers early. It explains what the test claims, what the research shows so far, and what is still unproven.

What's claimed

Galleri is a commercial blood test made by GRAIL. It's marketed as able to detect a shared biological "signal" across more than 50 types of cancer from one blood draw. It then predicts where in the body that signal is coming from. It's promoted directly to consumers. Some employers and clinicians offer it as an add-on to routine checkups. Ads and social posts often describe it as a way to "catch cancer early," broadly, in a single test.

The core scientific idea is real. Tumors shed fragments of DNA into the bloodstream. Galleri looks for chemical patterns (specifically, DNA methylation patterns) on that circulating cell-free DNA that differ from normal cell DNA. If the test finds a suspicious pattern, it reports a "cancer signal detected" result. It also estimates the most likely tissue of origin, meant to guide follow-up imaging or biopsies. Many of these cancer types — including some pancreatic, ovarian, and other aggressive cancers — currently have no recommended screening test at all. That's a big part of the test's appeal.

What the evidence actually shows

The most relevant published research comes from studies like PATHFINDER and its larger follow-up, PATHFINDER 2. GRAIL has published both in peer-reviewed journals. It also presented them at oncology conferences, including the 2026 ASCO Annual Meeting. PATHFINDER 2 enrolled nearly 36,000 adults age 50 and older with no cancer symptoms. The test flagged a cancer signal in 287 participants. Of those, 173 were later diagnosed with cancer.

Reported results:

• Specificity (how often people without cancer correctly get a negative result): around 99.6%, a false positive rate under 0.4%.
• Sensitivity (how often the test finds a cancer that is there): roughly 70% for a group of 12 especially deadly cancers, and lower, around 39%, when all cancer types were included.

When the test did detect a signal, it correctly predicted the tissue of origin about 91% of the time. A positive result was followed by an actual cancer diagnosis about 60% of the time.

Those numbers describe a test that, in this group, missed a real share of cancers. It also flagged some signals that didn't turn out to be cancer. Neither fact makes the test worthless. But neither one proves the test saves lives.

That distinction matters. Catching a cancer signal earlier isn't automatically the same as reducing deaths from cancer. Some early detection catches slow-growing cancers that were never going to cause harm. This is called overdiagnosis. Follow-up procedures for false signals carry their own cost, anxiety, and risk.

As of this writing, no completed randomized controlled trial has shown that using Galleri, or any multi-cancer early detection (MCED) test, lowers cancer deaths across a screened population. The National Cancer Institute says plainly that big open questions remain. The NCI-backed Cancer Screening Research Network is running its own multi-cancer detection research. One part of that work is a pilot called the Vanguard Study. It was built and funded independently of any single test maker, to help answer those questions.

Where it stands today

Galleri has not been approved or cleared by the FDA. GRAIL discloses this directly. The test is offered as a laboratory-developed test (LDT). It's run in GRAIL's own CLIA-certified, CAP-accredited lab, and it's available by prescription only. Laboratory-developed tests follow a different regulatory path than FDA-approved diagnostics. That path has historically involved less independent premarket review of a lab's specific performance claims. FDA oversight of LDTs is still an evolving, legally contested area. This is worth knowing before assuming "available from a doctor" means the same thing as "FDA approved."

Galleri is also not a substitute for guideline-recommended screening such as mammograms, colonoscopies, low-dose CT for eligible smokers, or cervical cancer screening. GRAIL's own materials say as much. The test doesn't detect a signal for every cancer type. Not all cancers shed detectable DNA into the blood. Both false positives and false negatives happen. It isn't recommended for people who are pregnant, under 22, or in active cancer treatment. A positive result needs a follow-up diagnostic workup. It isn't a diagnosis by itself. Cost is another real barrier. The test isn't currently covered by Medicare or most private insurance for average-risk screening. It typically runs several hundred to over a thousand dollars out of pocket, depending on the offer.

The bigger picture

Galleri is a genuinely new category of cancer test. The underlying science of detecting tumor DNA signatures in blood is an active, legitimate area of cancer research. But "available now" and "proven to save lives at a population level" are two different bars. Galleri has only cleared the first one.

Here's the honest picture today. It can detect real cancer signals in some people who wouldn't otherwise have been screened. It will also produce results that turn out not to be cancer. It will miss some cancers entirely. And nobody has yet shown, in a completed trial, that using it reduces cancer deaths.

Anyone considering it should talk with a clinician about what a positive or negative result would actually mean for them. They should also keep up with the screening tests that already have decades of evidence behind them for reducing deaths.

Sources

• National Cancer Institute, "Screening for Many Cancers with One Test: Uncertainty Abounds," Cancer Currents Blog: https://www.cancer.gov/news-events/cancer-currents-blog/2022/finding-cancer-early-mced-tests
• National Cancer Institute, "Cancer Screening Research Network Launches," press release: https://www.cancer.gov/news-events/press-releases/2024/cancer-screening-research-network-launches
• GRAIL, Galleri test product and disclosures page: https://grail.com/galleri-test/
• GRAIL, PATHFINDER 2 study results presented at the 2026 ASCO Annual Meeting (press release)

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.